Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DA8W3Q
|
|||
| Drug Name |
THR-149
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic macular edema [ICD-11: 9B71.02] | Phase 2 | [1] | |
| Company |
Oxurion
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Plasma kallikrein (KLKB1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | AndrogenReceptor Signaling Pathway | |||
| Panther Pathway | Blood coagulation | |||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | |||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04527107) A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema (KALAHARI). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Oxurion. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.